ATP13A2 antibody (PE)
Quick Overview for ATP13A2 antibody (PE) (ABIN1427815)
Target
See all ATP13A2 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human ATP13A2
-
Isotype
- IgG
-
-
-
-
Comment
-
Exitation/Emission: 480,565nm/578nm
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 100 μg/mL BSA, 50 % glycerol and 0.09 % sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at 4°C
-
Expiry Date
- 12 months
-
-
- ATP13A2 (ATPase Type 13A2 (ATP13A2))
-
Alternative Name
- Park9/Atp13a2
-
Background
-
ATP13A2 is a 1,180 amino acid multi-pass membrane protein that belongs to the P5 subfamily of ATPases which play an important role in the transportation of inorganic cations. Expressed as multiple alternative spliced isoforms, ATP13A2 functions to catalyze the conversion of ATP to ADP and a free phosphate, thereby participating in the active transport of ions across cellular membranes. Defects in the gene encoding ATP13A2 are the cause of Kufor-Rakeb syndrome (KRS), a rare hereditary type of Parkinson’s disease that exhibits juvenile onset and is characterized by neurodegeneration and dementia. The ATP13A2 gene maps to human chromosome 1, which spans 260 million base pairs, contains over 3,000 genes and comprises nearly 8 % of the human genome.
Subcellular location: Extracellular
Synonyms: AT132_HUMAN, Atp13a2, ATPase type 13A2, CLN12, HSA9947, KRPPD, PARK9, Probable cation transporting ATPase 13A2, Probable cation-transporting ATPase 13A2, Putative ATPase, RP1-37C10.4. -
Pathways
- Ribonucleoside Biosynthetic Process
Target
-